Tonix Pharmaceuticals prices $20M registered direct offering with Point72; shares and pre-funded warrants

Tonix Pharmaceuticals Holding Corp.

Sold 615,025 shares at $16.26 and pre-funded warrants for 615,025 shares at $16.259 to Point72; gross proceeds ~$20M.
Closing expected Dec 30, 2025; TD Cowen sole placement agent.
Net proceeds to fund commercialization, pipeline development, and working capital.
30-day lock-up on additional equity issuance; 180-day ban on variable rate transactions.
Directors and officers also subject to 30-day lock-up.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Placement Agency Agreement with TD Securities (USA) LLC valued at 6.0% cash placement fee on gross proceeds; expense reimbursement up to $100,000 (effective 2025-12-29).

Action: entry
Agreement: underwriting
Counterparty: TD Securities (USA) LLC
Value: 6.0% cash placement fee on gross proceeds; expense reimbursement up to $100,000
Effective: 2025-12-29

Exact text from the filing

On December 29, 2025, the Company entered into a placement agency agreement (the "Placement Agency Agreement") with TD Securities (USA) LLC (the "Placement Agent"), pursuant to which the Placement Agent was engaged as the placement agent for the Offering.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Securities Purchase Agreement with a single institutional investor valued at $20.0 million gross proceeds; offering price per Share $16.26, per Pre-Funded Warrant $16.259 (effective 2025-12-29).

Action: entry
Agreement: equity purchase
Counterparty: a single institutional investor
Value: $20.0 million gross proceeds; offering price per Share $16.26, per Pre-Funded Warrant $16.259
Effective: 2025-12-29

Exact text from the filing

On December 29, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with a single institutional investor (the "Purchaser").

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-25-021283

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.